Blog

Market Intelligence Digests

Daily AI-powered analysis of SEC, FDA, and US regulatory filings.

🇺🇸United States··daily

S&P 500 Consumer Staples Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (despite diverse tickers including biotechs, energy, and SPACs), mixed sentiment dominates (14/50 mixed), with revenue declines averaging ~10% YoY in 18 reporting companies (e.g., ARKO -12.3%, Intellinetics -8%, Sangamo -32%), offset by cost reductions narrowing net losses in 9/22 loss-reporting firms (e.g., Neumora -3% FY loss, ImmuCell -52%). Biotech/pharma filings (10+) highlight pipeline catalysts clustered in Q2-H2 2026, while energy/utilities show debt optimizations (Atmos extensions, Electra liabilities -44-99%). Capital allocation leans conservative with sparse dividends (ARKO $0.26/share, Brookfield $0.07/share) and no buybacks noted; cash runway extensions into 2027 common amid high burn. Portfolio-level trends reveal margin expansion in 7/15 (e.g., ImmuCell +44% gross profit) despite volume pressures, signaling operational resilience but macro headwinds. M&A/divestitures active (CVD SDC sale $16.9M Q2 2026 close, KEEMO control change), with AGMs/earnings imminent. Implications: Selective opportunities in catalysts and turnarounds, caution on cash burns and rev softness.

31 high priority19 medium50 total filings
🇺🇸United States··daily

S&P 500 Industrials Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (including adjacents like energy and materials), FY2025 results reveal mixed performance with standout revenue accelerations in niche growth areas (e.g., CBAK Energy Q4 +131.8% YoY to $58.8M driven by LEV +524%, Legence +21.5% to $2.55B fueled by data centers +50.1%) offset by widespread margin compressions (e.g., CBAK FY gross margin -1430bps to 9.4%) and net losses (12/20 10-Ks reported wider losses YoY). Refinancings strengthened balance sheets (Ingevity $750M rev facility, MediaAlpha $150M term loan), while M&A activity (Addentax 62% stake in Keemo Fashion, Hecla Quebec sale) and capital returns ($9B ConocoPhillips buybacks/dividends) signal confidence. Proxies (Baker Hughes, Conoco, S&T Bancorp) show low insider ownership (<1%) and standard governance with ownership guideline hikes. Forward catalysts include mid-2026 clinical readouts (Reviva Phase 3, Connect Biopharma Phase 2), April-May shareholder meetings, and AAN poster (AEON April 2026). Portfolio implications: Bullish on data/energy efficiency plays amid margin pressures; monitor going concern risks in biotechs (Reviva, Genprex, CISO). Actionable now: Favor refinanced industrials over loss-makers.

28 high priority22 medium50 total filings
🇺🇸United States··daily

S&P 500 Energy Sector SEC Filings — March 30, 2026

The S&P 500 Energy stream reveals proxy season kicking off with 10+ AGMs clustered in May 2026, highlighting strong 2025 performance at key players like ConocoPhillips (2,375 MBOED production, $19.8B cash ops, $9B shareholder returns including $5B buybacks/$4B dividends, 15% YoY Lower 48 drilling efficiency gains, $1B Marathon synergies). Devon Energy's proposed Q2 2026 merger with Coterra (mixed sentiment due to risks/no appraisal rights) signals consolidation amid neutral-to-positive sentiment overall. Portfolio-level trends show robust capital returns and operational efficiencies in upstream (COP) contrasting neutral governance disclosures elsewhere; COPT Defense (non-core but contextual) boasts 95% leased rates and exceeded 2025 scorecard (except one metric). No widespread margin compression or declines noted, with forward catalysts centered on virtual AGMs (May 12-21) and merger close. Baker Hughes discloses low insider ownership (<1%) and strict no-pledge policies. Mixed signals from non-energy filings (e.g., AParadise unproven DTC platform, Neogen exec departure) underscore energy focus purity but highlight M&A risks.

7 high priority5 medium12 total filings
🇺🇸United States··daily

Dow Jones 30 Stocks SEC Filings — March 30, 2026

Across the 50 filings in the USA Dow Jones 30 intelligence stream (primarily small/mid-cap proxies but including DJ30 names like Boeing and Baker Hughes), sentiment is mixed with 14 positive, 18 mixed, and 12 neutral/negative, reflecting resilient capital raises and M&A amid revenue volatility. Period-over-period trends show revenue growth in 8/22 reporting companies (avg +72% YoY where positive, e.g., CBAK Q4 +131.8%, Global Arena Q1 +72%), but declines in 14 (avg -15%, e.g., Soluna FY2025 -22%, ARKO -12.3%), with gross margins compressing broadly (avg -300bps in mixed reporters like CBAK 23.7% to 9.4%). Biotech firms dominate positive catalysts, narrowing net losses (avg -25%, e.g., Unicycive -28%, Reviva -33%) ahead of FDA milestones, while SPACs advance mergers (Vine Hill 92.6% approval). Capital allocation leans toward equity/debt raises ($142M Soluna, $112.5M Capstone) over dividends/buybacks (none noted), signaling growth focus but dilution risks. M&A completions (Leidos $2.4B, CVD SDC $16.9M) and credit amendments (Ingevity $750M revolver) highlight deal momentum, with DJ30 filings mostly neutral proxy boilerplate. Portfolio implication: Opportunistic buys in biotech/SPAC catalysts, caution on revenue-dependent industrials amid margin pressure.

37 high priority13 medium50 total filings
🇺🇸United States··daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, entertainment, and adjacent sectors), sentiment is predominantly mixed (14/50), with positive operational milestones (e.g., Sable Offshore oil resumption, Fermi $1.8B raised) offset by financial pressures like revenue declines (Helio -65% YoY), margin compressions (banks avg NIM down ~40bps), and impairments (Falcon's $8.3M). Key period-over-period trends show revenue growth in 12 firms averaging +45% YoY (outliers: Fathom +25%, Falcon's +121%), but net losses persisted or widened in 18 cases; gross margins expanded in retail (Lulus +640bps Q4) while compressing in finance/REITs (avg -150bps). Capital allocation favors dividends/special payouts (Sanfilippo $1.50, Blue Ridge $0.60, Brookfield $0.0721) over buybacks, with M&A/divestitures prominent ($142.8M Affinity merger, $292.5M Compass sale). Portfolio-level patterns indicate turnaround potential in retail/entertainment amid consumer softness, but risks from NPAs rising 200%+ in banks and ongoing deficits (Pacific Coast). Critical implications: near-term catalysts from Q2'26 AGMs/mergers offer arb plays; monitor deleveraging post-asset sales for alpha.

25 high priority25 medium50 total filings
🇺🇸United States··daily

S&P 500 Healthcare Sector SEC Filings — March 30, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (primarily biotech, pharma, med devices amid broader financials), dominant themes include robust M&A activity (BSX-Penumbra merger, Aurinia-Kezar acquisition) and FDA catalysts (Unicycive OLC PDUFA June 29, 2026), with mixed FY2025 financials showing 6/10 biotechs narrowing net losses YoY (avg -25%, e.g., Unicycive -28% to $26.6M) but rising G&A/R&D expenses averaging +40%. Period-over-period trends reveal healthcare innovators extending cash runways into 2027 (Unicycive $54.9M, Aura $144.2M) despite no revenues, contrasting with deteriorations like Ensysce net loss widening 28% to $10.2M and Interpace PancraGEN discontinuation post-CMS loss. Capital allocation leans toward equity raises (Artelo $11M private placement) and buybacks (News Corp $1B program), while non-healthcare filings (e.g., CIM REIT portfolio -1.6% YoY) dilute focus but highlight relative biotech resilience. Critical developments like Sight Sciences $34M patent win and ProCap merger approval signal upside, but risks from delistings (Interpace, Zivo) and going concerns (CISO) warrant caution. Portfolio-level, healthcare shows +9% avg revenue growth in reporting firms (CareView +9%) with margin stabilization, positioning for H2 2026 catalysts amid sector M&A premiums.

29 high priority19 medium48 total filings
🇺🇸United States··daily

S&P 500 Technology Sector SEC Filings — March 27, 2026

Across 25 SEC filings in the USA S&P 500 Technology stream (despite diverse sectors), proxy season dominates with 12+ DEF 14A/DEFA14A filings for May 2026 annual meetings (AMD May 13, Murphy Oil May 13, CBU May 20, TSQ May 11, CPT), highlighting governance, comp approvals, and equity plans amid mixed financial trends. Period-over-period data shows growth outliers like Community Financial System's 9.7% YoY revenue increase (+$72.1M), 15.4% diluted EPS growth, and Murphy Oil's 3% production rise to 182 MBOEPD with 20% LOE/BOE reduction, contrasted by declines such as Muzinich BDC's 28% YoY investment income drop to $17.1M and AIM ImmunoTech's $82k revenue decrease with halted sales. Tech-specific signals include AMD's proposed +65M share equity plan, Planet Labs' full warrant redemption reducing dilution, and BlockchAIn Digital Infrastructure's $500M+ AI data center LOIs. Capital allocation trends favor shareholder returns (Murphy $286M, CBU 2.2% dividend hike for 33rd year), with auditor changes routine (Sun Communities, Portsmouth Square). No clustered insider trading, but forward-looking catalysts like AIB's webinar and exec transitions (SBA retirement Dec 2026) point to monitoring AI infra demand and governance votes. Portfolio implications: Selective bullishness in growth proxies/AI, caution on income declines/supply risks.

14 high priority11 medium25 total filings
🇺🇸United States··daily

Nasdaq 100 Stocks SEC Filings — March 27, 2026

Across 32 filings from NASDAQ-100 constituents and related names, proxy season dominates with 15+ DEF/DEFA14A filings announcing May 2026 annual meetings, signaling routine governance but highlighting dividend growth (e.g., PepsiCo's 54th consecutive increase) and board refreshes. Period-over-period trends show mixed financial health: bullish growth in select names like Murphy Oil (production +3% YoY to 182 MBOEPD, LOE/BOE -20% to $10.89) and Community Financial System (revenues +9.7% YoY, EPS +15.4%), contrasted by widening losses in TMC the metals (-150% YoY Q4 net loss to $40.4M) and Muzinich BDC (investment income -28% YoY). Capital allocation leans shareholder-friendly with PepsiCo and Community boosting dividends, while operational risks persist in biotech (AIM ImmunoTech halted sales) and metals (TMC permitting delays). Vanguard's 13G/A amendments across Netflix, MSFT, PYPL, TSLA, WMG reflect passive realignments with no ownership shifts, maintaining stability in mega-caps. Portfolio-level, energy/financials outperform (avg +10% YoY metrics) vs metals/biotech underperformance (-20% avg), with May meetings as key catalysts for compensation votes and auditor ratifications. Implications: Favor dividend growers amid volatility, monitor biotech/metal turnarounds.

17 high priority15 medium32 total filings
🇺🇸United States··daily

S&P 500 Financials Sector SEC Filings — March 27, 2026

Across 50 diverse SEC filings from the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers alongside adjacent sectors), key themes include heightened M&A and restructuring activity (e.g., mergers at Two Harbors, Dillard's, Allegiant), routine proxy season launches with neutral sentiment, and mixed financial results showing revenue growth in 12/50 filings (avg +25% YoY where reported, e.g., Worthington +24%, Legence +34.6% Q4) but widening losses in biotechs/miners (e.g., TMC FY loss +290% YoY to $320M). Period-over-period trends reveal organic sales expansion (Worthington +14%) offset by margin compression (Worthington gross margin -40 bps, Legence Q4 -60 bps) and credit deterioration in financials (Avidia Bancorp charge-offs $21M, nonaccruals +406% YoY). Forward-looking catalysts cluster in H1 2026: spin-offs (AnaptysBio Apr 20), AGMs (May cluster), compliance plans (BiomX Apr 24), and raised guidances (Legence FY26 rev $3.7-3.9B, +42% midpoint YoY). Capital allocation leans shareholder-friendly with buybacks (Carnival $2.5B), dividends (Blue Owl monthly $0.0748/share), and refinancings (Delek Logistics new credit facility), but no broad insider trading patterns emerge. Portfolio implications: overweight M&A targets for near-term premiums, monitor bank credit risks amid NIM expansion (Avidia +40 bps to 3.29%), and favor revenue growers with liquidity buffers (Kailera $546M cash/secs). Overall sentiment mixed/neutral (32/50), with 10/50 positive on growth catalysts.

27 high priority23 medium50 total filings
🇺🇸United States··daily

S&P 500 Consumer Staples Sector SEC Filings — March 27, 2026

Across 50 diverse SEC filings (primarily proxies, 8-Ks, and 10-Ks, with limited true S&P 500 Consumer Staples representation like PEP, HAIN, MNST), proxy season dominates with 10+ annual/virtual meetings clustered in May 2026 (e.g., PEP May 6, F May 14, MNST May 14), signaling routine governance but opportunities in dividend votes and board refreshes. Period-over-period trends reveal revenue growth in outliers (Aurora Mobile +19% YoY to RMB 375M, MicroCloud +39% YoY to RMB 404M, Lifeloc +6% to $9M) but widespread declines in commodity funds (US Oil Fund assets -25.8% YoY to $37M, US NatGas -1.2% to $19M) and product revenues (Kopin -42% YoY to $8.4M); margins stable/flat in Lifeloc (40.3%) but implied compression in MicroCloud (~21% from 23%). Capital allocation highlights PEP's 54th consecutive dividend hike (June 2026 payment); forward-looking catalysts include drug sNDAs (BioXcel YE2026), Phase 3 readouts (Kodiak), and M&A (Clear Channel merger post-go-shop). Risks cluster around listing deficiencies (HAIN, Alight < $1 bids) and cyber incidents (CareCloud); portfolio-level theme: resilient servicing in 12+ Exeter ABS trusts but sector mismatches dilute staples focus, implying broader market stability amid energy/biotech volatility.

31 high priority19 medium50 total filings
🇺🇸United States··daily

S&P 500 Industrials Sector SEC Filings — March 27, 2026

Across 50 filings from S&P 500 Industrials and related sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A for Marriott, Murphy Oil, Aspen Aerogels, 3M, Norfolk Southern, Ampco-Pittsburgh, Camden), signaling routine governance with neutral sentiment but highlighting board changes and upcoming AGMs in May 2026. Financial results show mixed trends: strong revenue growth in industrials like Legence (+21.5% FY2025 to $2.6B, +34.6% Q4) contrasts with declines in tech-adjacent like Luminar (-12% YoY revenue to $66M), Phunware (-19.9% to $2.6M), and Ideal Power (-56% to $38k), while banks/financials like Avidia report net losses from credit deterioration (nonaccruals +406% YoY to $20M). M&A activity is bullish with Great Lakes Dredge tender at $17/share, Bank of Nagoya MOU for 2028 integration (synergies in assets ¥22T combined), and tuck-ins like Legence's Bowers Group. Capital returns strong at Banco Santander (EUR 3.5B dividends, share cancellations) and Murphy Oil ($286M free cash flow returned). Forward guidance positive for Legence (FY2026 rev $3.7-3.9B, up from prior), Aspen (Q1 2026 $38M settlement, 2027-2028 contracts), but risks from legal overhangs in student loan trusts and NYSE delisting warning for Alight. Portfolio-level: Industrials show resilient backlog growth (Legence +49% to $3.7B) amid margin pressures (Q4 gross margin -60bps to 20%), with catalysts clustered in May AGMs.

34 high priority16 medium50 total filings
🇺🇸United States··daily

S&P 500 Energy Sector SEC Filings — March 27, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, proxy statements dominate (4/7 filings for Ampco Pittsburgh and EOG Resources), signaling the start of 2026 proxy season with neutral sentiment and unanimous board recommendations FOR director elections, say-on-pay votes, and auditor ratifications at AGMs on May 8 (Ampco) and May 20 (EOG). Knightscope's FY2025 10-K provides the only substantive financials, revealing 5% YoY revenue growth to $11.3M (services +7% to $8.0M, products +1% to $3.4M) but sharply deteriorating gross margins to -42% from -34% (-800bps), operating loss expansion to $33.9M driven by 77% R&D surge to $12.5M, and net loss to $33.8M (+6.5% YoY), offset by cash build to $20.6M via $42.2M financing (+22% YoY). Hallador Energy reported a contestable MSHA imminent danger order at Oaktown Mine with no injuries or production halt (mixed sentiment), while Stoke Therapeutics completed a clean auditor switch to EY for FY2026 (neutral). No insider trading, M&A, or capital allocation details emerged; forward-looking focuses on 2026 auditors and AGMs. Sector themes include governance routine amid isolated profitability erosion and regulatory watch items, implying neutral portfolio positioning with low materiality (avg 6.4/10) but actionable AGM catalysts.

3 high priority4 medium7 total filings
🇺🇸United States··daily

Dow Jones 30 Stocks SEC Filings — March 27, 2026

Across the 50 filings for USA Dow Jones 30 constituents and related entities, M&A activity dominates with 10+ deals including Two Harbors' $10.80/share cash merger with CrossCountry Mortgage (closing H2 2026), Allegiant Travel's stock+cash acquisition of Sun Country (pro forma 2025 revenues $3.7B), and multiple JFB Construction/XTEND drone mergers highlighting defense synergies. Period-over-period trends show stark bifurcation: explosive revenue growth in digital assets (BitGo +424% YoY to $16.2B) and select financials (Indivior +4% to $1.24B, Adjusted EBITDA +20%), contrasted by declines in industrials/tech (Kopin Q4 revenues -42% YoY, SpringBig FY2025 -7.4%, SBC Medical FY2025 -15%). Positive clinical and defense catalysts (Kodiak Sciences Phase 3 success, XTEND $500M pipeline/$71M backlog) offset proxy-heavy neutral sentiment, with capital allocation favoring buybacks (Indivior $400M authorization) and financings ($30M CETI equity line, $56M Kopin placement). Portfolio-level margin trends mixed (Indivior +500bps to 35%, SBC -3pts to 40%), but overall bullish M&A wave implies sector consolidation; watch H2 2026 closings for blue-chip upside amid volatile growth patterns.

28 high priority22 medium50 total filings
🇺🇸United States··daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 27, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with outliers in energy/commodities, infra, and finance), proxy season dominates with 15+ DEF/DEFA14A filings signaling May 2026 AGMs for firms like Marriott, Ford, Equifax, and Haverty, focusing on director elections, comp approvals, and governance amid mixed 2025 results. Period-over-period trends show modest revenue growth in retail/furniture (Haverty +5% YoY sales, Lifeloc +6%), but sharp declines in commodity funds (oil/gas ETFs assets down avg 20% YoY, e.g., US 12 Month Oil -25.8%), widening losses in graphite/mining (GrafTech net loss to $219.8M from $131.2M), and narrowing losses in biotech (Werewolf -14% YoY). M&A activity surges with 8 deals/tenders (Great Lakes $17/share tender, JFB/XTEND $1.5B combo with $71M backlog/$500M pipeline, Shizuoka-Nagoya integration), signaling consolidation for synergies. Capital allocation leans conservative (dividends up at Community Financial 33rd year +2.2%, LM Funding >3.3M shares repurchased), with strong balance sheets (Haverty zero debt/$125M cash). Forward-looking catalysts cluster in mid-2026 M&A closings and Q1 2026 production ramps (Lifeloc SpinDetect), but risks from cash burn (Werewolf runway to Q4 2026) and covenant relaxations (OFS min NII cut to $1M). Overall, defensive retail outperforms volatile commodities, favoring M&A plays over pure consumer exposure amid cautious spending.

25 high priority25 medium50 total filings
🇺🇸United States··daily

S&P 500 Healthcare Sector SEC Filings — March 27, 2026

In the S&P 500 Healthcare stream, biotech filings dominate with widespread cost discipline driving net loss narrowing averaging 42% YoY across Werewolf Therapeutics (-14% to $60.8M), Kezar Life Sciences (-33% to $56M), Humacyte (-73% to $40.8M), and Alamar Biosciences (-37% to $29.8M), fueled by R&D cuts of 20-49% and G&A reductions of 17-21%. Revenue acceleration shines in diagnostics and providers: Alamar +195% YoY to $74.2M, IDEXX Laboratories +10% with EPS +23% to $13.08, Elevance Health +13% to $197.6B. Clinical catalyst from Kodiak Sciences' Phase 3 superiority in diabetic retinopathy offsets patent reaffirmation favoring Broad Institute at Editas Medicine. Cash runways vary, with Werewolf limited to Q4 2026 prompting strategic review incl. sale/merger. Mature firms prioritize returns (Elevance $4.1B repurchases/dividends) amid proxy season recaps. Portfolio implications: Biotech turnaround via op ex efficiency supports overweight on revenue-generating names like IDEXX/Humacyte; monitor IPOs, trials, and May AGMs for catalysts amid mixed sentiment (positive in 4/9 key health filings).

32 high priority18 medium50 total filings
🇺🇸United States··daily

S&P 500 Technology Sector SEC Filings — March 26, 2026

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

7 high priority6 medium13 total filings
🇺🇸United States··daily

Nasdaq 100 Stocks SEC Filings — March 26, 2026

Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.

11 high priority13 medium24 total filings
🇺🇸United States··daily

S&P 500 Financials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (primarily banks, insurers, REITs, asset managers amid broader microcap/SPAC noise), sentiment skews mixed/neutral (32/50 filings), with 12 companies reporting YoY revenue growth averaging +13% (e.g., Lumexa +7.8%, Leef Brands +22.1%) offset by 11 declines averaging -28% (e.g., CaliberCos -60.7%, STRATA -9%). Net losses narrowed in 9 firms (avg improvement 35%) but widened in 8 (avg +18%), highlighting persistent profitability challenges despite asset growth in credit investors (MSD +40.7%, AB Private +16.9%). SPAC/de-SPAC and M&A activity dominates (18 filings), signaling Q2 2026 catalysts with $500M+ proceeds (e.g., Xanadu, Suncrete). Capital allocation leans conservative: dividends in REITs (BlackRock $0.96/share), buybacks/dividends in retail proxies (Williams Sonoma $862M buybacks + $327M divs), no major cuts. Forward-looking guidance stable (Lumexa reiterates 2026 rev $1.045-1.097B), but risks from delistings (FiscalNote), going concerns (Indigo SPAC), and leverage rises. Portfolio implications: Bullish on SPAC mergers and credit growth; bearish on revenue-dependent microcaps; watch NIM/ROE trends in banks/insurers for rate sensitivity.

37 high priority13 medium50 total filings
🇺🇸United States··daily

S&P 500 Consumer Staples Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.

29 high priority21 medium50 total filings
🇺🇸United States··daily

S&P 500 Industrials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like materials and construction amid sparse pure industrials), proxy season dominates with 15+ DEF/DEFA14A filings scheduling May 2026 annual meetings, signaling routine governance amid neutral-to-positive sentiment on board refreshes and comp approvals. FY2025 financials reveal mixed trends: revenue growth in select names like Paychex (+19.8% YoY Q3) and Iridex (+8% FY), but widespread loss widening in biotechs (e.g., Acumen +19%, Upstream +128%) and margin pressures (e.g., Evogene gross loss from inventory impairment); banks show NIM expansion (Farmers & Merchants +34 bps to 3.02%) offset by deposit declines (-5%). Capital returns shine with Newmont's $1.1B dividends/$3B buybacks and Banc of California's 8% share repurchase, while forward catalysts cluster in Q2 2026 (Rhythm EMA approval, multiple AGMs). Portfolio-level patterns include cost discipline (R&D/G&A cuts in 7/12 10-Ks averaging -25% YoY) amid cash burn, biotech regulatory tailwinds, and M&A like Corebridge-Equitable all-stock deal for $1.5T AUM scale. Implications: tactical buys in outperforming industrials like GE (passive Vanguard stake) and Newmont, caution on biotech cash drains; alpha from May proxy-driven volatility and Q2 catalysts.

27 high priority23 medium50 total filings